CellaVision develops and sells instruments, software, and reagents for the analysis of blood and body fluids. The company automates parts of the sample preparation process and replaces manual microscopes with analysis instruments based on digital image analysis technology and artificial intelligence. Its business segments include analyzers, staining reagents, smearing and staining devices, and software applications. Key products include the DM1200, DM9600, DC-1, and the CellaVision Bone Marrow Aspirate Application. The company serves hematology laboratories of all sizes globally. CellaVision operates through an indirect sales model supported by long-term distribution agreements, primarily with major industry players. A central strategic partnership is maintained with Sysmex, which provides global reach and supports product launches. The company was founded in 1994 and listed on NASDAQ Stockholm in 2018. It acquired RAL Diagnostics in 2019 to enhance sample preparation capabilities and obtained exclusive rights to a patent portfolio on Fourier Ptychographic Microscopy in 2021. CellaVision generates recurring revenue from reagents, software updates, and service agreements.

Summarised from the company's own disclosures, fiscal year ended Dec 2025

Industry Medical Devices Homepage cellavision.com
Sector Healthcare IR page cellavision.com
Tags
digital cell morphology, hematology, laboratory automation, artificial intelligence, blood analysis, body fluid analysis, reagents, microscopy, diagnostics, sample preparation, CellaVision Bone Marrow Aspirate Application, DM1200, DM9600, DC-1, CellaVision Proficiency Software, CellaVision Advanced RBC software, CellaVision Academy, DIFF-Line, RAL Diagnostics, Sysmex, Sysmex SP-50, Sysmex DI-60, My.ral-diagnostics, Fourier-Ptykografisk Mikroskopi, Digital Cell Morphology Software
Press page cellavision.com/investors/press-releases

Metrics

Valuation  
Market cap kr 3.289B
Market cap (USD) $ 323.706M
P/E 21.48
PEG 2.40
P/BV 3.71
P/S 6.98
P/OCF 46.24
P/FCF —
Dividend yield 1.8%
Turnover / mcap —
Returns  
ROE 18.0%
ROI 17.0%
ROIC 17.7%
Profit margin 20.2%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 9.0%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 1.3%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 24
Quality score 52.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007
Revenue 758.968M 723.217M 677.292M 639.34M 565.552M 471.44M 461.772M 364.812M 309.312M 265.038M 239.39M 216.916M 179.851M 169.512M 155.402M 131.638M 108.974M 100.444M 74.565M
Net profit 153.078M 140.722M 130.309M 118.335M 125.339M 89.48M 99.172M 88.688M 69.723M 59.8M 52.822M 31.465M 18.932M 6.451M 14.633M 38.349M 27.72M 25.054M 2.625M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007
Share price 191.53 — 210 206.15 399.73 — — 148 148 84 — — — — — — — — —
Price performance 12m — — 0.02 -0.48 — — — 0 0.76 — — — — — — — — — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (SEK) — 71M 89.7M 97.6M 97.8M 103M 120M
↳ YoY growth +26.3% +8.8% +0.2% +5.1% +17.0%
↳ 5y CAGR +11.1%
Other receivables (SEK) — 23.5M 20.1M 15.1M 6.27M 15.4M 8.51M
Borrowings, current (SEK) — 45.9M 40.8M 42.1M 36M 14.2M 13.7M
Borrowings, non-current (SEK) — 86.9M 95.8M 60.4M 28.7M 12.7M 12M
Cash and deposits (SEK) 102M 102M 130M 108M 122M 149M 188M
Net debt (borrowings + leases - cash) (SEK) — 30.5M 6.37M -5.56M -56.9M -123M -163M
Cash flow detail
Operating cash flow (SEK) — 71.1M 160M 137M 196M 198M 201M
Purchases of property, plant and equipment (SEK) — -8.07M -13.7M -23.5M -31.8M -12M -18.8M
Purchases of intangible assets (SEK) — -64,000 -31.8M -201,000 0.00 — —
Change in receivables (cash effect) (SEK) — -6.29M -9.84M -3.33M 7.25M -15.8M -12.5M
Change in inventories (cash effect) (SEK) — -29.8M -31.1M -26.3M 12.6M -1.71M 4.62M
Change in payables (cash effect) (SEK) — 242,000 29M 849,000 -9.48M 2.1M 4.69M
Dividends paid (cash effect) (SEK) — 0.00 -17.9M -47.7M -53.7M -53.7M -59.6M
Interest paid (cash effect) (SEK) — -2.55M -1.87M -2.34M -3.26M -1.89M -886,000
Income taxes paid (cash effect) (SEK) — -20.9M -28.7M -27.1M -27.6M -26.2M -31.4M
Operating cash flow before change in receivables (SEK) — 77.4M 170M 141M 189M 214M 213M
Free cash flow (OCF - PPE - intangibles) (SEK) — 63M 114M 114M 165M 186M 182M
Income detail
Research and development expense (SEK) — 51.3M 64.2M 88.6M 83.3M 87.4M 97.6M
↳ 5y CAGR +13.7%
Total comprehensive income (SEK) — 81.2M 132M 146M 128M 153M 131M
Reported — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Organic sales growth:
Q3, 2026: 13.4% (2.6)

EBITDA margin:
Q3, 2026: 32% (28)

July 1st – September 30th, 2026
Net sales increased by 13.6% (-1.7) to SEK 200 m (176).
Sales increased organically by 13.4% (2.6), currency effect 0.1% (-4.3).
EBITDA increased to SEK 64 m (50).
EBITDA margin increased to 32% (28).
Profit before tax increased to SEK 51 m (39).
Earnings per share before and after dilution increased to SEK 1.68 (1.31).
Cash flow from operating activities increased to SEK 68 m (30).

Significant events during the period
The Extraordinary General Meeting on September 2, 2026, resolved, in accordance with the proposal from the Board of Directors, to adopt an employee option program for the company’s CEO.

CellaVision will host a Capital Markets Day on February 17, 2027, in Stockholm, Sweden. During the event, executive management will present the company’s updated strategic direction and priorities through 2030. Further information and a formal invitation will be provided closer to the event.

CellaVision AB (publ) will publish its report for the third quarter of 2026 on October 29, 2026, at 7:20 am CET. The report will be available at www.cellavision.com .

In connection with the release of the report, analysts, investors, and media are hereby invited to a conference call and webcast at 11:00 am CET, where Steve Ferguson, President & CEO, and Monica Jönsson, CFO, will present and comment on the report. The presentation will be in English.

To participate via webcast, please use the link below.
https://events.inderes.com/cellavision/q3-report-2026

 
To participate via conference call, please register at the link below. After registration, you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
https://events.inderes.com/cellavision/q3-report-2026/dial-in

No pre-registration is required. Please dial in 5-10 minutes before the scheduled start time to facilitate a timely start.

Prompts

CellaVision (ticker CEVI), listed in Sweden.

ETFs Holding CellaVision

ETF Weight in ETF Shares Market value As of
DFIS 0.00% 7,835 $ 158.103K Nov 12, 2026
DFIC 0.00% 5,125 $ 103.417K Nov 12, 2026
DFAI 0.00% 3,880 $ 78.295K Nov 12, 2026
AVDV 0.00% 6,527 $ 131.137K Nov 16, 2026